| 摘要 |
The use of an effective amount of a cholinomimetic agent for manufacture of medicaments for treating Alzheimer's patient by initially determining the presence of apolipoproteins E2 and E3 allele or the absence of apolipoprotein E4 allele from the peripheral tissues of a patient which is indicative of the degree of impairment in brain acetylcholine synthesis and nicotinic receptor activity, followed by the administration of an effective amount of the medicament. The cholinomimetic agent is selected from the group consisting of inhibitors of acetylcholine degradation, inducers of acetylcholine synthesis, acetylcholine agonists or mimics, and muscarinic M2-receptor antagonists.
|
